Skip to main content
. 2018 Aug 13;128(9):3926–3940. doi: 10.1172/JCI96519

Figure 7. AZD6738 attenuates coexpression of CD8+ T cell exhaustion markers and promotes CD8+ T cell effector function in CT26 tumors following radiation.

Figure 7

(A) Representative contour plots depicting PD-1 and LAG-3 expression on splenic and tumor-infiltrating (TIL) CD8+ T cells for the designated treatment groups at day 12. (B) Quantitation of the percentage of TIL CD8+ T cells that coexpress PD-1 and LAG-3 or PD-1 and Tim-3 at day 12. Data from 3 independent experiments per time point, each with 1–3 mice per arm. n at day 12 = 6 per arm (7 IR). (C) Representative contour plots depicting IFN-γ and TNF-α expression by splenic and tumor-infiltrating (TIL) CD8+ T cells for the designated treatment groups following stimulation with PMA/ionomycin at day 12. (D) Quantitation of the percentage of TIL CD8+ T cells that elicit IFN-γ or IFN-γ and TNF-α following stimulation with PMA and ionomycin at days 9 and 12. Day 9 data from 1 experiment with the IR/AZD6738 + IR arms and vehicle/AZD6738 arms staggered and harvested/stained on separate days. n at day 9 = 5 per arm (4 IR). Day 12 data from 3 independent experiments, each with 1–3 mice per arm, with harvesting/staining for all arms performed on the same day within a given experiment. n at day 12 = 5 vehicle, 6 AZD6738, 6 IR, 7 AZD6738 + IR. (B and D) Mean and SD bars shown. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ANOVA with Tukey’s multiple-comparisons test. Brackets not shown for comparisons that were not statistically significant.